Lancement d’une nouvelle génération d’instrument qPCR

http://novacyt.com/wp-content/uploads/2019/05/Novacyt-launches-next-generation-qPCR-instrument_final-13-05-19-FRENCH.pdf Compatible avec le catalogue Novacyt’s de plus de 550 tests moléculaires Paris, France et Camberley, UK – 13 mai 2019 – Novacyt (EURONEXT GROWTH : ALNOV; AIM: NCYT), spécialiste international du diagnostic clinique se félicite d’annoncer aujourd’hui que sa division moléculaire, Primerdesign, lance sa nouvelle génération d’instrument de test moléculaire genesig® q32 qPCR (“q32”), pour

Visit Page

LAUNCH OF NEXT-GENERATION qPCR INSTRUMENT

http://novacyt.com/wp-content/uploads/2019/05/Novacyt-launches-next-generation-qPCR-instrument_final-13-05-19-ENGLISH.pdf Compatible with Novacyt’s catalogue of over 550 molecular tests Paris, France and Camberley, UK – 13 May 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular business, Primerdesign, has launched its next-generation genesig® q32 qPCR molecular testing instrument (“q32”), to complement the already revenue generating

Visit Page

Conversion of Loan Notes

http://novacyt.com/wp-content/uploads/2019/05/Note-Conversion-ENGLISH.pdf Paris, France and Camberley, UK – 3 May 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces that, pursuant to the Convertible Bonds with Warrants Funding Programme (“Agreement”) announced on 23 April 2019, it has issued two tranches of new ordinary shares of €1/15 each (“Ordinary Shares”) to

Visit Page